Denied a Lifesaving Drug for a Rare Brain Cancer: A Mother’s Battle Over Coverage

A young man with a rare diffuse hemispheric glioma tried standard therapy without success and then an experimental pairing of the PARP inhibitor Lynparza (olaparib) with chemotherapy. His doctors sought coverage for the drug, but insurers and a county board denied it, prompting family advocacy and ultimately a donation from the drug maker’s program. After receiving the medicine for about two months, he died, underscoring how gaps in coverage for rare cancers can delay access to targeted treatments and force families to navigate complex, time‑consuming processes amid limited clinical guidance.